pegdinetanib

Pegdinetanib is an investigational anti-cancer drug that acts as a selective antagonist of vascular endothelial growth factor receptor 2 (VEGFR-2), thereby inhibiting tumor angiogenesis and the growth of new blood vessels in tumors[1][3][4]. It is a genetically engineered, pegylated peptide derived from human fibronectin using monobody technology, designed to be thermostable and protease-resistant[1][5]. Pegdinetanib was developed by Adnexus Therapeutics and Bristol Myers Squibb for intravenous administration. The drug entered Phase II clinical trials for glioblastoma, non-small cell lung cancer, and colorectal cancer but development has since been discontinued for these indications[3][4].

Brand names

Angiocept

Other names

AdnectinPEGDINETANIB